|1.||Bisgaier, Charles L: 3 articles (03/2008 - 05/2003)|
|2.||Marchesi, Marta: 3 articles (03/2008 - 12/2004)|
|3.||Nissen, Steven E: 2 articles (03/2011 - 11/2003)|
|4.||Sirtori, Cesare R: 2 articles (03/2008 - 03/2006)|
|5.||Nicholls, Stephen J: 1 article (03/2011)|
|6.||Kataoka, Yu: 1 article (03/2011)|
|7.||Uno, Kiyoko: 1 article (03/2011)|
|8.||Tardif, Jean-Claude: 1 article (09/2010)|
|9.||Balconi, Elena: 1 article (03/2008)|
|10.||Parolini, Cinzia: 1 article (03/2008)|
03/18/2008 - "These results confirm the efficacy of ETC-216 for atherosclerosis treatment and provide guidance for dose selection and frequency to obtain a significant reduction of plaque volume."
03/18/2008 - "More recently, regression of atherosclerosis was achieved in coronary patients by repeated infusions of ETC-216. "
03/18/2008 - "This study sought to evaluate in vivo the minimal dose of apolipoprotein (apo) A-I(Milano) phospholipid complex (recombinant apoA-I(Milano) and 1-palmitoyl-2-oleoyl phosphatidylcholine complexes [ETC-216]) able to induce atherosclerosis regression in a rabbit model of lipid-rich plaques. "
|2.||Acute Coronary Syndrome
03/01/2006 - "In a pilot study, ETC-216 showed a significant reduction in coronary plaque burden after five weekly treatments, assessed by intravascular ultrasound in patients with acute coronary syndrome. "
09/01/2010 - "In a pilot study, weekly infusions of ETC-216, a formulation of recombinant apoA-1 Milano, were administered at two doses for 5 weeks to patients beginning within 2 weeks of an acute coronary syndrome (ACS). "
|3.||Atherosclerotic Plaque (Atheroma)
11/05/2003 - "The study was a double-blind, randomized, placebo-controlled multicenter pilot trial comparing the effect of ETC-216 or placebo on coronary atheroma burden measured by intravascular ultrasound (IVUS). "
11/05/2003 - "The mean (SD) percent atheroma volume decreased by -1.06% (3.17%) in the combined ETC-216 group (median, -0.81%; 95% confidence interval [CI], -1.53% to -0.34%; P =.02 compared with baseline). "
11/05/2003 - "The primary efficacy parameter was the change in percent atheroma volume (follow-up minus baseline) in the combined ETC-216 cohort. "
|4.||Coronary Artery Disease (Coronary Atherosclerosis)
03/01/2011 - "While early evidence suggests that administration of ETC-216 promotes rapid regression of coronary atherosclerosis, bringing this compound to clinical practice will require further trials that evaluate its impact on cardiovascular events."
03/01/2011 - "ETC-216 for coronary artery disease."
|1.||Apolipoprotein A-I (Apolipoprotein A1)
|4.||apolipoprotein A-I Milano